Applied Molecular Transport (AMTI) – StreetInsider.com Reports
-
Applied Molecular Transport Inc. (AMTI) Tops Q3 EPS by 33c
-
Cyclo Therapeutics (CYTH) and Applied Molecular Transport (AMTI) Enter into Definitive Merger Agreement
-
Applied Molecular Transport (AMTI) Halted, News Pending
-
Chardan Capital Markets Downgrades Applied Molecular Transport (AMTI) to Neutral
-
Applied Molecular Transport cuts 57% of the workforce, explores strategic alternatives
-
Applied Molecular Transport (AMTI) approves workforce reduction of approximately 57%, to explore strategic alternatives
-
Applied Molecular Transport (AMTI) Halted, News Pending
-
Applied Molecular Transport (AMTI) Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial
-
Jefferies Downgrades Applied Molecular Transport (AMTI) to Underperform
-
BofA Securities Downgrades Applied Molecular Transport (AMTI) to Underperform
-
SVB Leerink Downgrades Applied Molecular Transport (AMTI) to Market Perform
-
JMP Securities Downgrades Applied Molecular Transport (AMTI) to Market Perform
-
Applied Molecular Transport (AMTI) Reports Top-line Phase 2 Results from LOMBARD Monotherapy Trial of AMT-101
-
Applied Molecular Transport (AMTI) PT Raised to $3 at Chardan Capital Markets
-
Applied Molecular Transport (AMTI) Granted FDA Orphan Drug Designation for AMT-101
-
Applied Molecular Transport (AMTI) granted FDA Orphan Drug Designation for treatment of pouchitis
-
UPDATE: Jefferies Downgrades Applied Molecular Transport (AMTI) to Hold
-
Applied Molecular Transport (AMTI) PT Lowered to $5 at BofA Securities
-
Applied Molecular Transport (AMTI) Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis Did Not Demonstrate Added Clinical Benefit
-
Applied Molecular Transport (AMTI) Reports Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101
-
Applied Molecular Transport (AMTI) to Report Top-line Phase 2 AMT-101 on July 6th, Before Market Opens
-
Applied Molecular Transport (AMTI) PT Lowered to $10 at BofA Securities
-
Applied Molecular Transport (AMTI) PT Lowered to $21 at SVB Leerink
-
Applied Molecular Transport (AMTI) PT Lowered to $50 at JMP Securities
-
Applied Molecular Transport (AMTI) Provides Strategy Update
-
Applied Molecular Transport (AMTI) PT Raised to $49 at BofA Securities
-
Applied Molecular Transport (AMTI) Reports Positive Top-line Phase 2 Results from FILLMORE of AMT-101
-
Applied Molecular Transport (AMTI) Announces Board Changes
-
Applied Molecular Transport (AMTI) Appoints Holly Schachner to its Board
-
Applied Molecular Transport (AMTI) Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress
-
Applied Molecular Transport (AMTI) PT Lowered to $86 at JMP Securities
-
Applied Molecular Transport (AMTI) Prices 2.5M Share Common Offering at $42/Sh
-
Applied Molecular Transport (AMTI) Announces Proposed 2.5M Share Public Offering of Common Stock
-
Applied Molecular Transport (AMTI) PT Raised to $75 as Jefferies Expects 'Transformative Data'
-
JMP Securities Starts Applied Molecular Transport (AMTI) at Market Outperform
-
Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 1a Trial of Oral AMT-126; Expands Clinical Pipeline
-
Applied Molecular Transport (AMTI) PT Raised to $74 at SVB Leerink
-
Companies with NDRs 10/30
-
Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis
-
UPDATE: Jefferies Starts Applied Molecular Transport (AMTI) at Buy
-
UPDATE: BofA Securities Starts Applied Molecular Transport (AMTI) at Buy
-
SVB Leerink Starts Applied Molecular Transport (AMTI) at Outperform
-
Applied Molecular Transport (AMTI) IPO Opens 57% Higher
-
Armitec, Inc. (AMTI) Prices 11M Share Common Offering at $14/Sh
-
ATMI (ATMI) Tops Q4 EPS by 5c; Guides
Back to AMTI Stock Lookup